Entity
Large-Scale Colorectal Cancer Proteomic Atlas
A newly released dataset of 1,000 proteomically and histologically profiled colorectal cancer cases refines tumor classification, identifying new functional subgroups within the chromosomally unstable class and a previously unrecognized rare subgroup. This resource is likely to become a reference point for future CRC biomarker and therapeutic stratification research.
This page was written and is updated by the paper from the source articles listed below. Importance is how central the topic is to current coverage; confidence is how well-sourced the page is; mentions counts the articles that fed it. How the wiki works →
## Overview
A newly published multimodal resource profiles 1,000 treatment-naive colorectal cancer (CRC) cases, described as the largest proteomically profiled CRC cohort to date, integrating deep proteomics, targeted genomics, whole-slide histopathology, and clinical follow-up (bioRxiv, Oct 21).
## Key Findings
- From proteomic data, researchers derived six molecular subgroups that recapitulate known MSI and mesenchymal classes, while further resolving the chromosomally unstable (CIN) class into three functional subgroups, including a previously unrecognized indolent subgroup with favorable outcomes (bioRxiv, Oct 21).
- The study also identifies a rare, previously unrecognized subgroup, suggesting additional molecular heterogeneity beyond current classification systems (bioRxiv, Oct 21).
## Why It Matters
Current CRC classification systems only partially capture tumor heterogeneity, limiting prognostic accuracy and treatment stratification. A large, clinically annotated proteomic resource of this scale could become a reference dataset for biomarker discovery, companion diagnostic development, and clinical trial stratification — of interest to pharma, diagnostics companies, and biotech licensing deals.
## Outlook
Expect this dataset/resource to be cited and built upon in subsequent CRC subtyping, biomarker, and drug-target studies; it may also factor into future diagnostic test development and related IP.